Work

Abstract LB041: THOR-707 (SAR444245), a novel not-alpha IL-2 as monotherapy and in combination with pembrolizumab in advanced/metastatic solid tumors: Interim results from HAMMER, an open-label, multicenter phase 1/2 Study

Year: 2021

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2021-lb041

Authors: Filip Janku, Raghad Abdul-Karim, Arun Azad, Johanna Bendell, Gerald Falchook, Hui K. Gan, Tira Tan, Judy S. Wang, Cheng Ean CHEE, Lina Ma, Jill Mooney, Neyssa Marina, Giovanni Abbadessa, Marcos Milla, Tarek Meniawy

Institutions: The University of Texas MD Anderson Cancer Center, Texas Oncology, Peter MacCallum Cancer Centre, Sarah Cannon, Tennessee Oncology, HealthONE, Austin Hospital, Austin Health, National Cancer Centre Singapore, Sarasota Memorial Hospital, National University Cancer Institute, Singapore, Linear Clinical Research

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3182697675

Cites:

Cited by: 26

Related to: 10